/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

L

Liza C. Villaruz

University of Pittsburgh(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

211

Papers

6.6K

Citations

29

h-index

53

i10-index

Liza C. Villaruz is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & Colorectal Cancer Treatments and Studies. The author has an h-index of 29, co-authored 180 publications.

ORCID: 0000-0001-7456-523X

Research Topics

Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Colorectal Cancer Treatments and Studies Pancreatic and Hepatic Oncology Research CAR-T cell therapy research

Papers by this author

works

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring <scp><i>BRAF</i></scp> mutations in the <scp>L</scp>ung <scp>C</scp>ancer <scp>M</scp>utation <scp>C</scp>onsortium

2014 · Cancer · 122 citations

https://doi.org/10.1002/cncr.29042

Liza C. Villaruz Mark A. Socinski Shira Abberbock Lynne D. Berry

Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours

2011 · British Journal of Cancer · 36 citations

https://doi.org/10.1038/bjc.2011.285

Hussein Tawbi Liza C. Villaruz Ahmad A. Tarhini Stergios J. Moschos

MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603

2015 · Clinical Epigenetics · 19 citations

https://doi.org/10.1186/s13148-015-0092-2

Liza C. Villaruz Grace Huang Marjorie Romkes John M. Kirkwood

Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma

2024 · Lung Cancer · 15 citations

https://doi.org/10.1016/j.lungcan.2024.107928

Aaron S. Mansfield Jun Vivien Yin Penelope A. Bradbury David J. Kwiatkowski

604O Phase I dose escalation and initial dose expansion results of AMG 193: A MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors

2024 · Annals of Oncology · 9 citations

https://doi.org/10.1016/j.annonc.2024.08.671

Adrian G. Sacher Miguel A. Villalona‐Calero Bert H. O’Neil J. Rodon

A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2

2023 · EClinicalMedicine · 7 citations

https://doi.org/10.1016/j.eclinm.2023.102317

Khvaramze Shaverdashvili Vincent Reyes Hong Wang Dhaval Mehta

Research topics

topics

Lung Cancer Treatments and Mutations

Cancer Immunotherapy and Biomarkers

Colorectal Cancer Treatments and Studies

Pancreatic and Hepatic Oncology Research

CAR-T cell therapy research

Chat about Author

Papers

Chat

Click to start Chat